Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for prevention of progression from early inflammatory back pain to ankylosing spondylitis
NL-OMON36697Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS) comparing Etanercept with Placebo (2 arms). Primary endpoints: Disease activity and clinical response, Short-term MRI inflammation reduction and 1 more. Started Nov 2009; status: active, not recruiting.
02
Drugs
etanercept
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON36697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36697.